본문 바로가기
KERD
논문KCI 등재

Glutamine-mediated epigenetic regulation of cFLIP underlies resistance to TRAIL in pancreatic cancer

최경철|손재경|신동명|Kim Eun-Young|장은주|Kim Ji Hye|Lee Jinyoung|Im Se Seul|Kim Boyun|Min Hyo-Jin|Heo Jinbeom
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2024.12|Experimental and Molecular Medicine|제56권 |pp. 1013-1026|DOI 10.1038/s12276-024-01231-0

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent because it kills cancer cells while sparing normal cells. However, many cancers, including pancreatic ductal adenocarcinoma (PDAC), exhibit intrinsic or acquired resistance to TRAIL, and the molecular mechanisms underlying TRAIL resistance in cancers, particularly in PDAC, remain unclear. In this study, we demonstrated that glutamine (Gln) endows PDAC cells with resistance to TRAIL through KDM4C-mediated epigenetic regulation of cFLIP. Inhibition of glutaminolysis significantly reduced the cFLIP level, leading to TRAIL-mediated formation of death-inducing signaling complexes. Overexpression of cFLIP dramatically rescued PDAC cells from TRAIL/Gln deprivation-induced apoptosis. Alpha-Ketoglutarate (aKG) supplementation significantly reversed the decrease in the cFLIP level induced by glutaminolysis inhibition and rescued PDAC cells from TRAIL/Gln deprivation-induced apoptosis. Knockdown of glutamic-oxaloacetic transaminase 2, which facilitates the conversion of oxaloacetate and glutamate into aspartate and aKG, decreased aKG production and the cFLIP level and activated TRAIL-induced apoptosis. AKG-mediated epigenetic regulation was necessary for maintaining a high level of cFLIP. Glutaminolysis inhibition increased the abundance of H3K9me3 in the cFLIP promoter, indicating that Gln-derived aKG production is important for Jumonji-domain histone demethylase (JHDM)-mediated cFLIP regulation. The JHDM KDM4C regulated cFLIP expression by binding to its promoter, and KDM4C knockdown sensitized PDAC cells to TRAIL-induced apoptosis. The present findings suggest that Gln-derived aKG production is required for KDM4C-mediated epigenetic regulation of cFLIP, which leads to resistance to TRAIL.

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent because it kills cancer cells while sparing normal cells. However, many cancers, including pancreatic ductal adenocarcinoma (PDAC), exhibit intrinsic or acquired resistance to TRAIL, and the molecular mechanisms underlying TRAIL resistance in cancers, particularly in PDAC, remain unclear. In this study, we demonstrated that glutamine (Gln) endows PDAC cells with resistance to TRAIL through KDM4C-mediated epigenetic regulation of cFLIP. Inhibition of glutaminolysis significantly reduced the cFLIP level, leading to TRAIL-mediated formation of death-inducing signaling complexes. Overexpression of cFLIP dramatically rescued PDAC cells from TRAIL/Gln deprivation-induced apoptosis. Alpha-Ketoglutarate (aKG) supplementation significantly reversed the decrease in the cFLIP level induced by glutaminolysis inhibition and rescued PDAC cells from TRAIL/Gln deprivation-induced apoptosis. Knockdown of glutamic-oxaloacetic transaminase 2, which facilitates the conversion of oxaloacetate and glutamate into aspartate and aKG, decreased aKG production and the cFLIP level and activated TRAIL-induced apoptosis. AKG-mediated epigenetic regulation was necessary for maintaining a high level of cFLIP. Glutaminolysis inhibition increased the abundance of H3K9me3 in the cFLIP promoter, indicating that Gln-derived aKG production is important for Jumonji-domain histone demethylase (JHDM)-mediated cFLIP regulation. The JHDM KDM4C regulated cFLIP expression by binding to its promoter, and KDM4C knockdown sensitized PDAC cells to TRAIL-induced apoptosis. The present findings suggest that Gln-derived aKG production is required for KDM4C-mediated epigenetic regulation of cFLIP, which leads to resistance to TRAIL.

참고문헌 (47)

  1. Encarnacion-Rosado, J., "Harnessing metabolic dependencies in pancreatic cancers", Nat. Rev. Gastroenterol. Hepatol, 18, pp.482~492 (2021)
  2. Connor, A. A., "Pancreatic cancer evolution and heterogeneity:integrating omics and clinical data", Nat. Rev. Cancer, 22, pp.131~142 (2022)
  3. D’Arcy, M. S., "Cell death : a review of the major forms of apoptosis, necrosis and autophagy", Cell Biol. Int, 43, pp.582~592 (2019)
  4. Morana, O., "The apoptosis paradox in cancer", Int. J. Mol. Sci, 23, pp.1328~ (2022)
  5. Carneiro, B. A., "Targeting apoptosis in cancer therapy", Nat. Rev. Clin. Oncol, 17, pp.395~417 (2020)
  6. Wong, S. H. M., "The TRAIL to cancer therapy : hindrances and potential solutions", Crit. Rev. Oncol. Hematol, 143, pp.81~94 (2019)
  7. Deng, D., "TRAIL of hope meeting resistance in cancer", Trends Cancer, 6, pp.989~1001 (2020)
  8. Pavlova, N. N., "The hallmarks of cancer metabolism : still emerging", Cell Metab, 34, pp.355~377 (2022)
  9. Yoo, H. C., "A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells", Cell Metab, 31, pp.267~283 (2020)
  10. Martinez-Outschoorn, U. E., "Cancer metabolism : a therapeutic perspective", Nat. Rev. Clin. Oncol, 14, pp.113~ (2017)
  11. Son, J., "Glutamine supports pancreatic cancer growth through a KRAS regulated metabolic pathway", Nature, 496, pp.101~105 (2013)
  12. Wong, C. C., "Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches", Oncogene, 36, pp.3359~3374 (2017)
  13. Izzo, L. T., "The bidirectional relationship between cancer epigenetics and metabolism", Annu. Rev. Cancer Biol, 5, pp.235~257 (2021)
  14. Recillas-Targa, F., "Cancer epigenetics : an overview", Arch. Med. Res, 53, pp.732~740 (2022)
  15. Ge, T., "Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities", Cancer Commun. (Lond), 42, pp.1049~1082 (2022)
  16. Kim, J. H., "Enhanced glycolysis supports cell survival in EGFR-mutant lung adenocarcinoma by inhibiting autophagy-mediated EGFR degradation", Cancer Res, 78, pp.4482~4496 (2018)
  17. DeNicola, G. M., "Cancer’s fuel choice : new flavors for a picky eater", Mol. Cell, 60, pp.514~523 (2015)
  18. Yang, X., "TRAIL and curcumin codelivery nanoparticles enhance TRAIL induced apoptosis through upregulation of death receptors", Drug Deliv, 24, pp.1526~1536 (2017)
  19. Mauro-Lizcano, M., "Glutamine metabolism regulates FLIP expression and sensitivity to TRAIL in triple-negative breast cancer cells", Cell Death Dis, 9, pp.205~ (2018)
  20. Yerbes, R., "Limiting glutamine utilization activates a GCN2", TRAIL-R2, Cell Death Dis, pp.2022, 13[DOI]
  21. Micheau, O., "NF-kappaB signals induce the expression of c-FLIP", Mol. Cell Biol, 21, pp.5299~5305 (2001)
  22. Khan, M. A., "Oxidative stress induced by curcumin promotes the death of cutaneous T-cell lymphoma(HuT-78)by disrupting the function of several molecular targets", Mol. Cancer Ther, 11, pp.1873~1883 (2012)
  23. Fulda, S., "Targeting c-FLICE-like inhibitory protein(CFLAR)in cancer", Expert Opin. Ther. Targets, 17, pp.195~201 (2013)
  24. Seo, S. U., "NOX4-mediatedROSproduction induces apoptotic cell death via down-regulation of c-FLIP and Mcl-1 expression in combined treatment with thioridazine and curcumin", Redox Biol, 13, pp.608~622 (2017)
  25. Xu, R., "Reprogramming of amino acid metabolism in pancreatic cancer : recent advances and therapeutic strategies", Front Oncol, 10, pp.572722~ (2020)
  26. Bott, A. J., "Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism", Cell Rep, 29, pp.1287~1298 (2019)
  27. Park, S. J., "Enhanced glutaminolysis drives hypoxia-Induced chemoresistance in pancreatic cancer", Cancer Res, 83, pp.735~752 (2023)
  28. Mates, J. M., "Glutaminases regulate glutathione and oxidative stress in cancer", Arch. Toxicol, 94, pp.2603~2623 (2020)
  29. Yoo, H. C., "Glutamine reliance in cell metabolism", Exp. Mol. Med, 52, pp.1496~1516 (2020)
  30. Gao, X., "Metabolic interactions with cancer epigenetics", Mol. Aspects Med, 54, pp.50~57 (2017)
  31. Wu, H., "Reversing DNA methylation : mechanisms, genomics, and biological functions", Cell, 156, pp.45~68 (2014)
  32. Hoffmann, I., "The role of histone demethylases in cancer therapy", Mol. Oncol, 6, pp.683~703 (2012)
  33. Wang, L., "A small molecule modulates jumonji histone demethylase activity and selectively inhibits cancer growth", Nat. Commun, 4, pp.2035~ (2013)
  34. Labbe, R. M., "Histone lysine demethylase(KDM)subfamily 4 : structures, functions and therapeutic potential", Am. J. Transl. Res, 6, pp.1~15 (2013)
  35. Bayo, J., "Jumonji inhibitors overcome radioresistance in cancer through changes in H3K4 methylation at double-strand breaks", Cell Rep, 25, pp.1040~1050 (2018)
  36. Zhang, Q. J., "Histone lysine dimethyl-demethylase KDM3A controls patho logical cardiac hypertrophy and fibrosis", Nat. Commun, 9, pp.5230~ (2018)
  37. Qin, J. Z., "Targeting glutamine metabolism sensitizes melanoma cells to TRAIL-induced death", Biochem. Biophys. Res. Commun, 398, pp.146~152 (2010)
  38. Dilshara, M. G., "Glutamine deprivation sensitizes human breast cancer MDA MB-231 cells to TRIAL-mediated apoptosis", Biochem Biophys. Res. Commun, 485, pp.440~445 (2017)
  39. Eniafe, J., "The functional roles of TCA cycle metabolites in cancer", Oncogene, 40, pp.3351~3363 (2021)
  40. Morrison, A. J., "Cancer cell metabolism connects epigenetic modifications to transcriptional regulation", FEBS J, 289, pp.1302~1314 (2022)
  41. Simpson, N. E., "Modifying metabolically sensitive histone marks by inhibiting glutamine meta bolism affects gene expression and alters cancer cell phenotype", Epigenetics, 7, pp.1413~1420 (2012)
  42. Kaelin, W. G. Jr., "Influence of metabolism on epigenetics and disease", Cell, 153, pp.56~69 (2013)
  43. Jin, H., "A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer", Elife, 9, pp.e56749~ (2020)
  44. Yang, D., "Branched-chain amino acid catabolism breaks glutamine addiction to sustain hepatocellular carcinoma progression", Cell Rep, 41, pp.111691~ (2022)
  45. Safa, A. R., "c-FLIP, a novel biomarker for cancer prognosis, immunosuppression, Alzheimer’s disease, chronic obstructive pulmonary disease (COPD), and a rationale therapeutic tar get", Biomark J, 5, pp.4~ (2019)
  46. Ozturk, S., "Cellular FLICE-like inhibitory proteins(c-FLIPs) : f ine-tuners of life and death decisions", Exp. Cell Res, 318, pp.1324~1331 (2012)
  47. Ivanisenko, N. V., "Regulation of extrinsic apoptotic signaling by c-FLIP : towards targeting cancer networks", Trends Cancer, 8, pp.190~209 (2022)

관련 논문AI추천

Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potentialChen Yuyu, Han Yaqian, Jiang Xianjie, Liao Qianjin, Li Jinyun, Lin Jinguan, Oyang Linda, Peng Mingjing, Peng Qiu, Tang Yanyan, Tan Shiming, Wu Nayiyuan, Xia Longzheng, Xu Xuemeng, Yang Wenjuan, Yang Yiqing, Zhou Yujuan생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer CellsJang Won-Jun, Jeong Chul-Ho, Kim Dong-Hwan, Kim Dong Joon, Park Seong-Jun한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2025 · 제35권 Targeting glutamine metabolism as a therapeutic strategy for cancer최연경, Byun Jun-Kyu, Jin Jonghwa, Park Keun-Gyu생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma양소미, 이정신, 이지민, Ji-Yeon Lee, Jueun Kim생화학분자생물학회 · BMB Reports2023 · 제56권 제11호The emerging intertwined activities of metabolism and epigenetics unveils culprits and prospects in cancerLindroth Anders M., Verma Ayushi생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권 BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level김지혜, 노진경, 신동명, 임세슬, 장은주, Hwang Sein, Kim Jongwook, Lee Ji Hyeon, Son Jaekyoung생화학분자생물학회 · Experimental and Molecular Medicine2021 · 제53권

이 간행물의 다른 논문 (218건)

Big data and deep learning for RNA biologyJeon Hyeonseong, Baek Daehyun, Hwang Hyeonseo, Yeo Nagyeongpp. 1-29RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinomaXu Yanan, Ke Shanjia, Lu Shounan, Bai Miaoyu, Yu Hongjun, Yin Bing, Wang Chaoqun, Feng Zhigang, Li Zihao, Huang Jingjing, Li Xinglong, Qian Baolin, Hua Yongliang, Fu Yao, Sun Bei, Wu Yaohua, Ma Yongpp. 1-14Molecular mechanisms of circular RNA translationKim Yoon Ki, Hwang Hyun Jungpp. 1-9The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolismKim Ho, Yun Hye Jin, 이종호, Lee Su Bin, Kim Seok-Ho, Park Yun-Yong, Park Su Hwan, Ju Jin-Sung, Woo Hyunmin, Győrffy Balázs, Kim Eun-jeong, Han Hee Dong, Eyun Seong-ilpp. 1-15Neuron type-specific optogenetic stimulation for differential stroke recovery in chronic capsular infarctKim Ra Gyung, Cho Jongwook, Park Ji-Young, Kim Young Ro, Lee Min-Cheol, Kim Hyoung-Ihlpp. 1-11
원문 보기